Publicaciones en colaboración con investigadores/as de Hospital Infanta Leonor (149)

2026

  1. Altered placental expression of neurotransmitter and stress-related molecules in first-episode psychosis during pregnancy: Implications for cytoarchitecture and function

    Psychoneuroendocrinology, Vol. 186

  2. Beyond COVID-19 in people with HIV: Specific miRNA expression profile persist after SARS-CoV-2 clearance

    Journal of Infection and Public Health, Vol. 19, Núm. 3

  3. Clinical outcomes of long-acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real-world data from the Spanish RELATIVITY cohort

    HIV Medicine, Vol. 27, Núm. 1, pp. 58-73

  4. Closing the PrEP access gap in Europe: a strategic framework for equity and innovation among difficult-to-reach populations

    Journal of Antimicrobial Chemotherapy, Vol. 81, Núm. 3

  5. Comparable Inflammatory and Metabolic Outcomes after Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults with HIV (INSTINCT/GESIDA10918 Study)

    Clinical Infectious Diseases, Vol. 82, Núm. 2, pp. e262-e274

  6. Corrigendum to “Beyond COVID-19 in people with HIV: Specific miRNA expression profile persist after SARS-CoV-2 clearance” [J Infect Public Health 19 (3) (2026) 103108]

    Journal of Infection and Public Health

  7. Corrigendum to “Beyond COVID-19 in people with HIV: Specific miRNA expression profile persist after SARS-CoV-2 clearance” [J Infect Public Health 19 (3) (2026) 103108] (Journal of Infection and Public Health (2026) 19(3), (S1876034125004575), (10.1016/j.jiph.2025.103108))

    Journal of Infection and Public Health

  8. Defining ascending aorta dilatation in pediatric bicuspid aortic valve: Comparison of known classical and new z-score nomograms, and anthropometric parameters indexing for its assessment

    Journal of Cardiology, Vol. 87, Núm. 4, pp. 375-382

  9. Delphi expert document on therapeutic adherence in patients with cardiovascular disease: Barriers, facilitators, and clinical implications

    REC: CardioClinics

  10. Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the RELATIVITY cohort

    AIDS, Vol. Publish Ahead of Print

  11. Dietary Patterns in a Nationwide Cohort of Patients with Hereditary Fructose Intolerance

    Nutrients , Vol. 18, Núm. 5

  12. Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort

    Journal of the International AIDS Society, Vol. 29, Núm. 4

  13. Exploring Mechanical Synchrony and Myocardial Work Across Different Pacing Locations Within the Left Bundle Branch

    JACC: Clinical Electrophysiology

  14. Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort

    AIDS (London, England), Vol. 40, Núm. 4, pp. 414-427

  15. Lipidomics uncovers metabolic manifestations related to liver steatosis and low-grade systemic inflammation in diet-treated hereditary fructose intolerance patients

    Clinical nutrition (Edinburgh, Scotland), Vol. 59, pp. 106608

  16. Long-acting cabotegravir and rilpivirine in people with HIV and obesity: Real-world outcomes from the RELATIVITY cohort

    HIV Medicine, Vol. 27, Núm. 5, pp. 690-709

  17. Longitudinal changes in circulating biomarkers from baseline to week 48 in treatment-Naïve people living with HIV initiating integrase inhibitor-based antiretroviral therapy

    PLOS ONE, Vol. 21, Núm. 2 February

  18. Peer review in Revista de Patología Respiratoria

    Revista de Patologia Respiratoria, Vol. 29, Núm. 1, pp. 1-2

  19. Prognostic Value of Blood Epigenetic Biomarkers of Aging in Persons With Well-Controlled HIV-1 Infection

    Clinical Infectious Diseases, Vol. 82, Núm. 4, pp. 583-591

  20. Real-world observational study to evaluate the effectiveness and safety of direct oral anticoagulants compared with vitaminK antagonists for secondary venous thrombosis prevention in low-risk thrombotic antiphospholipid syndrome patients: DOACS-APS protocol

    Revista Clinica Espanola